on 09 Aug 2022
Last Applicant/ Owned by
Suite 300E
Washington
DC
20037
Serial Number
88819345 filed on 03rd Mar 2020
Registration Number
6815599 registered on 09th Aug 2022
Filing Basis
1. intent to use
2. use application currently
Disclaimer
"TASIMELTEON CAPSULES"
The mark consists of the word "Hetlioz" on a first line, and "(tasimelteon) capsules" on a second line, with an arc of eleven solid circles of increasing size connecting the first and second lines of text. Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations, containing tasimelteon, for use in the treatment of sleep dRead More
Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations, containing tasimelteon, for use in the treatment of sleep disorders
01st Dec 2020
01st Dec 2020
No 88819345
No Service/Collective Mark
No VAND-0129US3
No
No
No
No
No
No
No
No
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
The mark consists of the word "Hetlioz" on a first line, and "(tasimelteon) capsules" on a second line, with an arc of eleven solid circles of increasing size connecting the first and second lines of text.
| Status Date | Action Taken |
|---|---|
| 09th Aug 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 09th Aug 2022 | REGISTERED-PRINCIPAL REGISTER |
| 07th Jul 2022 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 06th Jul 2022 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 09th Jun 2022 | ASSIGNED TO EXAMINER |
| 21st Apr 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| 21st Apr 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 11th Apr 2022 | USE AMENDMENT FILED |
| 11th Apr 2022 | TEAS STATEMENT OF USE RECEIVED |
| 12th Oct 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
